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Challenges and perspectives in continuous
glucose monitoring
Benjamin Jasha van Enter* and Elizabeth von Hauff *
Diabetes is a global epidemic that threatens the health and well-being of hundreds of millions of people.
The first step in patient treatment is to monitor glucose levels. Currently this is most commonly done
using enzymatic strips. This approach suffers from several limitations, namely it requires a blood sample
and is therefore invasive, the quality and the stability of the enzymatic strips vary widely, and the patient
is burdened by performing the measurement themselves. This results in dangerous fluctuations in
glucose levels often going undetected. There is currently intense research towards new approaches in
glucose detection that would enable non-invasive continuous glucose monitoring (CGM). In this review,
we explore the state-of-the-art in glucose detection technologies. In particular, we focus on the
physical mechanisms behind different approaches, and how these influence and determine the accuracy
and reliability of glucose detection. We begin by reviewing the basic physical and chemical properties of
the glucose molecule. Although these play a central role in detection, especially the anomeric ratio, they
are surprisingly often overlooked in the literature. We then review state-of-the art and emerging
detection methods. Finally, we survey the current market for glucometers. Recent results show that past
challenges in glucose detection are now being overcome, thereby enabling the development of smart
wearable devices for non-invasive continuous glucose monitoring. These new directions in glucose
detection have enormous potential to improve the quality of life of millions of diabetics, as well as offer
insight into the development, treatment and even prevention of the disease.
Introduction
Diabetes Mellitus is a global epidemic which affects almost 1 in
10 people.1,2 The World Health Organization (WHO) expects
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that more than 1/2 billion adults will suffer from diabetes
within the next decade.2 According to the International Diabetes
Federation (IDF), more people have died in recent years from
diabetes-related complications (5mio) than from HIV/AIDS
(1.5mio), tuberculosis (1.5mio) and Malaria (0.6mio) combined.1
The disease is categorized into two groups. In diabetes type I,
the body does not produce insulin and is unable to regulate
glucose levels without external intervention. In diabetes type II
the body is resistant to insulin, and does not properly control
and maintain healthy glucose levels. In both cases, the risks of
hypo- (low glucose levels) and hyperglycaemic (high glucose)
levels are dangerous and can result in serious health problems
and premature death. Acute hypoglycaemia can cause patients
to fall into coma, can induce seizures and result in death.
Chronic hyperglycaemia results in organ, nerve, cardiovascular,
and retinal damage.3–5
The first and most important step in treating diabetes
patients is maintaining healthy glucose levels. This requires
continuous, accurate monitoring of glucose levels over the day.
Healthy blood glucose levels are very constant: between 4–7 mM,6
or 70–120 mg dL1, while diabetic glucose levels fluctuate widely,
between 2–30 mM7 or 35–550 mg L1. Methods for accurate and
reliable glucose detection are crucial for correctly and effectively
diagnosing hyper and hypoglycaemia.
Conventional methods for glucose detection are biochemical.
A blood sample is provided on a strip or substrate containing
oxidizing enzymes. The reaction flux is then monitored by
measuring either electrical or optical changes in the enzymatic
substrate. This approach requires blood samples, and is there-
fore invasive. Further, the patients are burdened with the
responsibility of monitoring their own glucose levels, and most
patients need to perform intermittent measurements through-
out the day. Critical fluctuations in the glucose levels may
therefore go unnoticed either due to low patient compliance or
unexpected side effects related to factors such as changes in
insulin treatment, unknown food ingredients, and variations in
hormone levels.4
Further, enzymatic detection of glucose has limited accuracy.
The most common errors in detection are related to the quality
of the enzymatic strips and patient error. Most strips can be
stored for two years under ideal conditions, however the lifetime
is significantly reduced by environmental stress, such as elevated
temperature and oxygen (e.g. changes in altitude). Low quality
strips may additionally not have complete enzyme coverage.
Simple errors, such as testing with unwashed hands, will further
reduce the accuracy of the measurement.4,8–10 Many patients are
not aware that the measurement requires that a specified
volume of blood is deposited on the strip in order to convert
the measurement signal to a glucose concentration. Glucose
meters do not register sample volume, therefore variations in
sample volume may lead to errors in the calculation of glucose
concentration.11 In addition, the enzymatic strips are selective
for specific glucose conformations. Factors such as temperature
and pH influence the equilibrium ratio of these molecular
conformations. While the temperature and pH of blood is
relatively constant, the slow interconversion between molecular
conformations of the glucose molecule may be very relevant for
glucose detection in other body fluids, such as sweat. In this
case, fluctuations in temperature can result in non-equilibrium
conditions. Lastly, using enzymes means that the strips can only
be used once, or for a short period of time. As many diabetics
will use anywhere between 5–20 strips each and every day, this
leads to accumulated cost and waste.
New approaches for glucose detection that target the physi-
cal rather than the chemical properties of the molecule may
overcome these current limitations. Ideally glucose detection
could be performed not in blood, but in the interstitial fluid
that surrounds the fragile nerve cells. Current research efforts
in the field are focused on glucose detection through the
skin, or in bodily fluids such as sweat, tears and saliva. To do
this, new technologies with increased detection sensitivity and
reliability are needed.
Non-invasive methods to detect glucose would enable a new
paradigm in glucose monitoring. Patients could follow the
progression of their glucose levels over time, allowing them to
detect and quickly treat extreme fluctuations in glucose levels.
Continuous glucose monitoring would vastly improve the quality
of life for diabetes patients as well as aid in the understanding of
diabetes development and prevention.3,12–15 Continuous glucose
monitors would also be very helpful for dieticians to find out
individual responses to food, as this can strongly differ.16
The topics of glucose sensing and continuous glucose
monitors have been covered in excellent reviews. Bruen et al.
(2017) review the most recent advances in glucose sensors for
different bodily fluids.6 Wang et al. (2015) reviewed recent
advances in electrochemical sensing.3 Lin et al. (2017) focussed
on key challenges and recent advances in the field and provide an
extensive focus on newcomers in the market.17 McCaul et al. (2017)
survey several technologies and the accompanying challenges
and opportunities with specific focus on sweat analysis.18 Kim
et al. (2018) reviewed the recent advances for non-invasive
technologies using interstitial fluid and sweat.19 Oliver et al.
(2009) review and explain the background behind technologies
used for glucose sensing.20 The different factors analysed in
these review articles highlight the multidisciplinary approach
necessary for tackling the problems.
This review focusses on the physical mechanisms of glucose
sensing, with the aim of identifying approaches that provide
the required sensitivity and reliability to enable continuous,
non-invasive glucose monitoring. For this, a detailed under-
standing of glucose concentrations, and the time lag with
respect to blood, as well as fluctuations in pH and temperature
in different body fluids is needed. Glucose concentrations in
blood, interstitial fluid, sweat and tears, are correlated. Blood
has the highest glucose levels, and the continuous decrease
in glucose concentration from blood to the skin presents a
bottleneck for non-invasive glucose detection. We discuss the
glucose concentrations in these fluids, and the experimental
work on correlating their values. This provides a guideline for
the required sensitivity of glucose detection with non-invasive
approaches. In order to understand the full scope of the current
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properties of glucose. Strangely, this is often overlooked in the
literature, although the complex properties of the glucose mole-
cule are critically important when developing new approaches in
glucose detection. The conventional enzymatic approach for
glucose detection is described, along with detection limitations.
We then review recent non-enzymatic approaches with examples
and future prospects. Finally we survey the field of commercially
available as well as emerging glucose detection technologies.
Notably, the current market consists entirely of enzymatic glucose
detectors, with a single exception (Eversense Senseonics). This
demonstrates the urgency of addressing the potential and
limitations of current approaches in non-invasive glucose detec-
tion, and the need for more research in this direction. We note
that some state-of-the-art technologies will be missing from
this review because the market is very competitive and thus
patents are pending and innovations are not always published.
While many non-invasive approaches for glucose detection are
being researched, there are still many hurdles to overcome for
commercialization. Finally, an overview will be given on the
technologies in the current market for glucose monitoring.
Standards for accuracy in glucose
detection
Measuring glucose accurately is the first step in diabetes
patients’ wellbeing and care. The accuracy of self-monitoring
of blood glucose determines how well the patients are able
to monitor and react to fluctuations in their glucose levels.
Accuracy is how close the mean value is to the true concen-
tration, while precision is how much measurement points vary
with respect to one another.
Since 2013 the International Organisation of Standardization
(ISO) requires glucose meters to provide measurements within a
15% margin of the real concentration.21 The chart below shows
this comparative accuracy of a glucometer (Fig. 1). 95% of the
data must be in zone A, while 99% must be in zones A and B. In
the glucose sensing community, accuracy is commonly defined
in terms of the Mean Absolute Relative Difference (MARD). MARD
is a way of defining how accurate the detection method with
respect to another (accurate) system, usually the well-established
Yellow Springs Instrument (YSI) 2300 chemical analyser. There
are, however, no standardized ways to determine the accuracy
and precision of glucose meters. This means that this is not
necessarily a barrier for glucometers to enter the market.9 Besides,
sensors produced before 2013 do not necessarily meet the new,
stricter guidelines.
Several comparison studies on commercial glucometers have
revealed that many commercial self-testing devices do not meet
the required standards when subjected to laboratory testing
conditions. According to Freckmann et al. (2012) 80% of the most
popular commercially available glucometers provide readings
within the (pre 2013) ISO limits of a 20% margin.9 Only half the
glucometers measured provided readings within a 10% range
of the true concentration (shown as relative bias% in Fig. 2). In
2016 another comparison was published where it was shown
that none of the (anonymously) tested glucometers were within
the 10% margin proposed by the FDA.23 Ekhlaspour et al.
(2017) performed a recent comparative study, and showed that
just 7 of the 17 tested glucometers (test-strip-based) met the ISO
2003 standards, while only 2 (!) met the ISO 2013 criteria
(Table 1).24 The MARD of these 17 glucometers ranged from
5.6% to 20.8%. The only continuous glucose monitor found to
be within the required 10% limit was the DEXCOM G5.13
These comparative studies analyzed commercially available
glucometers. The results highlight the challenges faced by emerging
technologies for non-invasive glucose detection that target body
fluids with lower glucose concentrations than blood. These new
glucose sensors must be able to detect low glucose concentrations
with accuracies that meet increasingly strict standards.
Fig. 1 Clarke’s error grid analysis shows the accuracy zones for glucose
detection. The y-axis depicts the measured data from the glucometer, and
the x-axis depicts data from a reference biochemical analyzer (usually YSI
2300). Reprinted from ref. 22 with permission from Elsevier.
Fig. 2 Comparison of the accuracy of different commercially available
glucometers depicted in terms of relative bias (%). From Freckmann et al.
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It is challenging to strictly assess and compare the accuracy
of different emerging technologies for glucose detection in the
literature. While commercially available glucometers are evaluated
according to international standards, emerging technologies are
commonly characterized according to the smallest concentration
of analyte that can be detected, the limit of detection (LOD).
The anomeric properties of glucose
Interestingly, in the field of glucose detection, the properties of
the glucose molecule, and how these impact detection accuracy,
are often overlooked. While the properties of blood are very
stable, the pH, temperature, and composition of other body
fluids fluctuate over time. This impacts the anomeric ratio of
glucose molecules in the body fluid. For detection approaches
that are anomer-specific, e.g. enzymes, this can lead to errors
and unreliable readings, as the timescale for anomer equili-
bration (hours) is significantly longer than the time needed to
perform the measurement (seconds). New approaches for non-
invasive, continuous glucose sensing that target body fluids with
more volatile properties than blood must account for these
effects. In this section we review the anomeric properties of
glucose, and the potential impact on glucose detection accuracy.
Glucose is a simple sugar and a primary source of energy in
the human body, and one of the most abundant carbon-based
molecules in nature. As with other sugars/carbohydrates, the
structure and chemistry of glucose is complex. To explain the
important differences between carbohydrates, one has to start
with the term chirality. A chiral center is a carbon atom which
has 4 different substituents (groups). Each chiral center has 1 of
2 different structures, called either R or S. An R or S structure
can lead to significant differences between two molecules.
Carbohydrates have several chiral centers, resulting in unique
structures. Mannose, glucose, galactose, gulose, and altrose are
examples of molecules that only differ from one another by
chirality. These molecules are called stereoisomers, which
means that they have the same chemical formula, the same
chemical bonds, but different 3-dimensional configurations.
Generally the number of stereoisomers a molecule has is
given by 2n, where n is the number of chiral centers. Glucose
(C6H12O6) contains five chiral centers, and belongs to the
aldohexose group, composed of 16 stereoisomers. There are
16 stereoisomers and not 32, due to the anomeric carbon.
Glucose itself forms two stereoisomers, L-glucose and D-glucose.
The L and D form are mirror images of each other, i.e. enantiomers.
Both L-glucose and D-glucose are chemically stable, but only
D-glucose is found in nature. When we refer to glucose in this
review, we are referring to D-glucose. The glucose molecule is
also known as glucopyranose, dextrose, or its systematic name
(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal.
In aqueous solutions, one linear chain and two cyclic forms
of glucose exist in a dynamic equilibrium. Over 99% of glucose
molecules exist in one of the two cyclic six member (pyranose)
forms, while less than 1% of glucose molecules are in the open
chain configuration. The chain, g-D-glucose, is not thermo-
dynamically stable, but serves as an intermediate for conver-
sion between the cyclic forms. The closing of g-D-glucose can
happen at 2 different angles, producing an anomer with either
an R or S chiral center: a-D-glucose or b-D-glucose. The inter-
conversion between a-D-glucose and b-D-glucose via the linear
chain g-D-glucose is shown in Fig. 3.
As only 1 chiral carbon differs, the subclass of stereoisomers
are known as anomers (only applicable for sugars) or epimers.25,26
The location of this chiral center is known as the anomeric
carbon. The a and b anomers differ only in the orientation of
one of the OH groups, but have different chemical properties. In
a-D-glucose the OH-group is in the axial position at the anomeric
carbon, while in b-D-glucose the OH-group is in the equatorial
position (Fig. 3). In carbohydrate chemistry the general rule is that
the axial position (a-D-glucose) is more stable than predicted by
theory, known as the anomeric effect. Two major factors influence
the preferential position of the substituent at the anomeric
Table 1 Commercial test strip brands for glucose monitoring ranked by
Mean Average Relative Difference (MARD). The columns indicate which
brands met the ISO 2003 and 2013 standards for glucose detection (data
adapted from Ekhlaspour et al. (2017))24
Brand MARD (%) ISO 2003 ISO 2013
Contour Next 5.6 Yes Yes
StatStrip Xpress 6.3 Yes Yes
OneTouch VerioIQ 7.1 Yes No
Accu-Chek Nano 7.3 Yes No
FreeStyle Freedom Lite 7.5 Yes No
Accu-Chek Aviva Plus 7.6 Yes No
FreeStyle Lite 8.2 Yes No
Nova Max 9.7 No No
TRUEresult 13.0 No No
HemoCue Glucose 201 13.2 No No
OneTouch Ultra2 13.6 No No
ReliOn Prime 14.3 No No
BREEZEs 2 15.8 No No
ReliOn Micro 16.0 No No
AgaMatrix PRESTO 16.2 No No
AgaMatrix JAZZ 16.7 No No
SideKick 20.8 No No
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carbon: polarity of the solvent and the substituent groups.27
Water is highly polar and glucose has relatively small groups,
and glucose in physiological conditions is (unusually) more
prevalent in the equatorial position (b-D-glucose) over the axial
position (a-D-glucose).
In the chair conformation the OH group at the anomeric
centre of the b-anomer is in the equatorial position, which is
more stable.25,28 It points away from the molecule resulting in
less steric hindrance and less electric repulsion.
The precise mechanism of the interconversion of glucose
anomers is not yet fully understood, and thus it is the focus of
extensive experimental and theoretical research.28–33 Fig. 4
shows a schematic of the energy diagram, including the activa-
tion energy EA required for interconversion between the cyclic
and linear forms of glucose. Depending on the properties of the
solvent, the a-D-glucose or b-D-glucose form may be more
favorable. Intra- and intermolecular hydrogen bonds (mainly with
water) play a large role in the difference in stability between the
anomers.30,32 Further the ratio of a to b glucose anomers depends
on temperature and pH, as well as concentration, and solute.7,31,34
Basic conditions prefer b-D-glucose, and acidic conditions prefer
a-D-glucose.34 Interconversion between the anomers is very slow; it
takes hours for the equilibrium to be reached.
Generally the glucose molecule is very stable, and therefore
difficult to detect chemically. However, a-D-glucose and b-D-glucose
can be distinguished from one another by some enzymes, and they
have different functions in the body.35,36 Some enzymes can react
with both anomers, for example hexokinase (the starting enzyme
for glycolysis) and glucokinase, albeit with some selectivity for
the b anomer.7,37,38 Due to the selectivity of enzymes, humans
can digest both a and b glucose (with some preference for b),
but can only digest polymers of a-D-glucose. The difference
between a-D-glucose polymers and b-D-glucose polymers is
striking: polymers of a-D-glucose are starches, whereas poly-
mers of b-D-glucose are cellulose (in addition, each following
glucose molecule is inverted in the chain). Other enzymes,
including the most popular enzyme for glucose detection,
glucose oxidase (GOx), is specific for b-D-glucose, therefore
the pH of the sample must be known for accurate glucose
readings.7,37,39 The temperature and pH of blood are very
constant, and the ratio of b :a glucose is assumed steady at a
similar ratio as in water, 64 : 36.7,25 Total glucose concentrations
in blood samples can therefore be calculated with a glucose
meter based on the concentration of oxidised b-glucose.
The anomeric effect can pose a serious challenge for the
detection of glucose40 in body fluids other than blood. For
example, if the pH drops to 5.5 for over an hour, the ratio of the
anomers have shifted, but not yet reached equilibrium. This
means that glucose detection with anomeric-selective enzymes,
such as GOx, may not yield reliable results.
Glucose concentrations in different
bodily fluids
Traditionally urine was used to establish whether a patient
was diabetic, as in contrast to healthy patients, the urine of
untreated diabetics with hyperglycaemia contains glucose. For
the treatment of patients, however, blood is the most common
body fluid to use for glucose detection. Blood is relatively easy
to obtain and the measurement of blood glucose levels is well
established. Moreover, glucose concentrations in blood are
relatively high, and therefore enable good detection accuracy
and reliability. Further the temperature, pH and composition
of blood are very constant, which improves detection accuracy
and reliability. However the extraction of blood samples is
invasive and uncomfortable. Approaches towards non-invasive
glucose detection have targeted other body fluids such as
interstitial fluid,15,41,42 sweat,43–46 saliva,47 tears14 and even
breath.6,7,14,43,48–50
The challenge in establishing less invasive glucose testing
on these body fluids is that the glucose concentrations are
lower, while the composition of the body fluid is variable. This
means that non-invasive technologies must be able to reliably
detect low concentrations of glucose in fluids with varying pH,
temperature, and time delay (time lag) in glucose concentra-
tions (defined in comparison to blood glucose levels). This may
require additional sensors and/or frequent calibration of the
glucose sensor to ensure reliable readings.
Table 2 summarizes the different body fluids used for
glucose detection, as well as the advantages and disadvantages
of using these fluids to monitor glucose levels. The importance
of the pH value in glucose measurements should be noted.
While blood pH is constant between 7.35–7.45, the pH of sweat
can strongly vary due to the presence of lactic acid. The pH of
interstitial fluid varies widely, as in contrast to blood, there are
few buffering molecules to regulate pH. Due to the accumulation
of lactic acid on the skin, the pH values of sweat is even more
volatile. The time lag represents the time required for fluctua-
tions in blood glucose levels to be detected in other body fluids.
Although promising results have been reported, measuring
blood glucose levels non-invasively through the skin is proble-
matic due to the heterogeneous distribution of tissue types.52,53
A logical choice of fluid for minimally invasive to (ideally) non-
invasive glucose measurements is interstitial fluid. Interstitial
fluid is directly linked to the blood stream, with a time lag of
Fig. 4 Energy diagram of the 3 forms of D-glucose. The rate of inter-
conversion between glucose forms is determined by the activation energy
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about 10 minutes. Though blood glucose levels will give earlier
warnings, interstitial fluid may actually a more relevant
measurement fluid for diabetics because it is closer to the
nerve endings and damage occurs when the glucose levels of
the interstitial fluid fluctuate.51
Using saliva for glucose measurements presents several
challenges and not many advantages, as the composition varies
widely and it may be inconvenient. Sweat monitoring is gaining
popularity, especially because it is non-invasive and comfortable
for patients, but individual calibration and a high pH variance
means that more research is required to obtain reliable readings.
In addition, it would even be an appreciated monitoring fluid for
athletes. Athletes could follow the state of their body through
glucose measurements as well as lactic acid measurements.
Lactic acid is produced by overly exerting the muscles, and is
thus an indication of muscle fatigue. Ocular fluid (tear fluid) is
also promising, and glucometers may one day be easily inserted
into contact lenses. One of the major advantages is that stability
is not an issue due to the fact that contact lenses are replaced
regularly anyways.
Enzymatic glucose sensors
Nearly every glucose sensor on the market does not measure
glucose directly, but measures the reaction product arising
from glucose molecules that react with an oxidizing enzyme.
The most popularly used enzyme is glucose oxidase (GOx),
followed by glucose dehydrogenase (GDH). The measurement
is performed by puncturing the skin to retrieve a blood sample,
which is then deposited on a substrate containing glucose
oxidase. The volume of blood used for the reaction is controlled
through the size of the sample chamber.4
The b-D-glucose anomer reacts with GOx to form gluconic acid.
Gluconic acid then undergoes a further reaction, depending on
the generation of biosensor. A calibrated glucometer measures
the reaction flux to determine the glucose concentration. The
glucometer detects this by monitoring changes in either the
electronic or optical properties of the strip. The optical detection
is usually colorimetric, based on the change of colour in the
strip. The electrical detection is amperometric,7 and records the
change in conductivity of the strip.
The catalytic centre of the enzyme GOx is flavin adenine
dinucleotide (FAD). The FAD is reduced to FADH2 during the
oxidation of glucose. To measure the glucose concentration,
FADH2 is oxidized back to FAD, and each generation of glucose
biosensors does this in a different way (Fig. 5). The first generation
uses hydrogen peroxide. The second generation uses a mediator
such as ferricyanide. Finally, the third generation directly oxidizes
FADH2 through electron transfer from the electrode.
Table 2 Summary of the different body fluids used for glucose detection, the potential advantages and disadvantages of targeting these body fluids
for glucose detection, and the time lag in changes in glucose concentration with respect to blood
Bodily fluid Advantages Disadvantages Time lag (min)
Blood Highest concentrations (2–40 mM) Invasive —
Relatively easy to extract
Stable pH (7.35–7.45)
Interstitial fluid High concentrations (2–20 mM) pH varies from 6.6–7.65 0–45
Fluid surrounding nerve endings Microneedles or implants are
usually necessary
(avg. 8–10)51
Some research is done measuring
through the skin
Sweat Easy sample collection pH varies between 4.5–7 20, but lags behind
after interstitial fluid48





Easily accessible pH varies from 6.5–7.6 5–306,50
Mildly invasive
Low volume50
Tears from emotion and fro irritation
differ in composition50
Saliva Easy sample collection pH varies strongly from 5–8 15–2050




Fig. 5 Schematic depicting the three generations of enzymatic glucose
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Glucose detection using GDH measures both a-D-glucose
and b-D-glucose. Glucose detection using GOx only measures
the b-D-glucose anomer, so the ratio of a-D-glucose and
b-D-glucose needs to be known to calculate the total glucose
concentration.54 Thus, for enzymatic detection of glucose, the
anomeric effect may need to be accounted for. Due to the stable
pH and temperature in blood, the glucose anomeric ratios are
assumed to remain constant, and it is straightforward to calcu-
late glucose concentrations, even with detection approaches that
are sensitive to only a single anomer. For bodily fluids which vary
in pH and even temperature this is more difficult, especially if
the pH fluctuates, as it takes time for the anomers to reach
equilibrium.
The big disadvantage of enzymatic approaches is that the
detection relies on one-way substrates that must be continuously
replaced. Besides the accumulated cost and production of waste,
this is a bottleneck for long term use of continuous glucose
monitors. However, the current top-of-the-line commercially
available enzymatic-based continuous glucose monitors last for
up to two weeks and show promising results. Among others
Abbott’s FreeStyle Libre, Medtronics and DEXCOM’s G5.
More information on these commercially available continuous
glucometers is presented in the chapter covering the current
market.
Hospital laboratories and research facilities apply more
sophisticated equipment for glucose detection than patients
and general practitioners (GPs). One example is the popular YSI
chemical analyser. These chemical analysers are large and
expensive, but can detect a range of metabolites, including
b-D-glucose, hydrogen peroxide, lactic acid, ethanol, glutamate,
lactose, and sucrose, using a variety of specialized enzymatic
sensors, all with high accuracy and precision (MARD of 2%).
Typically, comprehensive biochemical analysis is too expensive
for GPs and small medical practices. Smaller machines offer a
less comprehensive metabolite analysis, for example, the Bio-
sen analysers measure glucose and lactate in blood samples.
For more information on enzymatic sensors, readers are
referred to the review by Heller and Feldman (2008) and by
Ferri et al. (2011).56,57
Electrical and electrochemical approaches
Enzymatic detection can be combined with more sophisticated
detection strategies to yield higher detection accuracy. For
example electrical and electrochemical measurements combined
with enzymatic detection can be performed on body fluids
containing lower glucose concentrations than blood. Several
research groups have made extraordinary advances in glucose
monitoring using this approach. Below, some of these novel
technologies are introduced.
Often, enzymes are mixed or bound to the electrode materials
in order to increase sensitivity. Lee et al. (2017) made a flexible
patch that can easily be attached to the skin and which monitors
glucose concentrations in sweat.45 The device measures glucose
electrochemically using highly selective electrodes. The electrodes
consist of porous gold to increase the electrode active area, and
coated with GOx. A negatively charged nafion layer is used to
immobilize the enzyme and simultaneously block diffusion
of negatively charged ions which can falsify the measurement.
A humidity sensor is used to detect when the critical sweat
volume for measurement has been obtained. The sensor works
for one day without calibration. The device even includes a drug
feedback delivery system, using microneedles for treating
diabetes patients. The long term stability of the GOx electrode
remain an issue.
Similarly, a sweat-monitoring device was reported that
measures a range of metabolites and properties of sweat in
order to calibrate the glucose measurement: glucose, lactic
acid, K, Na, pH, and temperature.46,58 The glucose and lactate
were both monitored with amperometric measurements. The
glucose sensors work for just 2 hours before needing replace-
ment. While the electrodes for electrolyte detection need to be
calibrated, no calibration is needed for the glucose and lactic
acid detection. The gold electrodes are coated with an electro-
chemically deposited Prussian Blue layer, followed by a layer of
mixed polysaccharide chitosan/GOx/single-wall carbon nano-
tubes. As the potassium concentration in sweat is constant,
this metabolite can be used as a measurement reference.6 An
important parameter for sensor design and calibration is that
the glucose concentrations vary over the body, meaning that
sweat from the armpit varies from lower back sweat.59
Zinc oxide (ZnO) electrodes functionalized with GOx were
combined with impedance measurements to detect glucose,
resulting in measurements. The results yielded readings
within 15% of the values using TRUEresult glucometer, which
has a reported 95% accuracy.44 The LOD was reported to be
0.1 mg dL1 (0.06 mM).
Zhang et al. (2018) also used ZnO (nanowires) in combination
with GOx, but in their setup no external battery power is needed.60
The device relies on electricity from the piezo-enzymatic-reaction
coupling on the GOx/ZnO. Piezoelectric response is due to a
potential from mechanical stress (in this case through muscle
movements). The device can monitor glucose in real-time and was
successfully tested on mice while it showed an LOD of 0.019 g L1
(0.1 mM).
Yehezkeli et al. fabricated electrodes using GDH and gold
nanoparticles.61 These electrodes are oxygen insensitive due to
the flavin dependency of the GDH. Their approach enabled
detection of glucose concentrations as low as 60 mM.
Yao and Zhang fabricated a paper based electrochemical
device using carbon-based electrodes and GOx, specifically for
detection of uric acid and glucose in urine.62 The limit of
glucose detection was 0.35 mM.
A further innovative approach consisted of ‘‘tattooing’’ electrodes
in the skin in order to extract interstitial fluid.42 The interstitial
fluid was collected by iontophoresis, and then analysed by
an enzymatic amperometric system. A special gel was applied
to prevent the issue of skin irritation from iontophoresis.
Vega et al. (2017) has done a proof-of-concept study on tattoos
in which GOx is in the ink, and the colour of the tattoo is
related to the glucose concentration of the skin.63
Tear sensors also exist, as a contact lens with biosensors.
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do not need to be stable for a long period of time, and thus
enzymatic sensors are a practical choice. The problems arising
from the use of contact lenses are battery power due to lack of
space and interference in glucose detection by other analytes.6,50
Park et al. innovated on this concept by applying GOx in a
soft contact lens combined with transparent nanomaterials.64
Catalase (another enzyme) was included to break down hydrogen
peroxide, thereby increasing the GOx sensitivity.
Liui et al. created a glucose sensor for tears and saliva using
GOx mixed with DNAzyme.65 The ‘‘pistol-like’’ DNAzyme (PLDz)
performed a self-cleavage reaction when in contact with hydrogen
peroxide. The LOD was 5 mM.
Contact-less detection can also be combined with enzymatic
detection. The detection of glucose oxidation can be done with
optical spectroscopy if a marker is used to colour the solution
after the oxidization of glucose (in this case using GOx). This
way, very low glucose concentrations can be measured.
Colorimetric measurements have the same basis as electro-
chemical measurements, but instead of the current being
measured, the amount of reactant is measured through a
change of colour. This change of colour is induced by a reaction
between hydrogen peroxide and a peroxidase. Colorimetric
measurements continues to demonstrate promising results.
Recently, Kim et al. applied nanoceria (cerium oxide) for
colorimetry to improve detection sensitivity.66
An optical technique that is promising – although still in the early
stages – is a metal waveguide capillary (MWC) compact photometer
for measuring glucose in nanomolar concentrations.67 This
detection method uses absorption and scattering to detect
glucose. Usually such setups are quite large, which isn’t practical
for patient glucometers. Miniaturisation is an important aspect
in setups where light refracts because the further away the
sensor is, the easier it is to detect the different wavelengths. By
using a reflective metal capillary between the sample and the
sensor, light is confined, but the angle can still be measured and
detection is enhanced 3000-fold compared with commercially
available spectrophotometers, namely an LOD of 5.12 nM.
Non-enzymatic glucose sensors
The benefit of enzymatic sensors is that they are specific
for glucose, thereby enabling good detection accuracy under
controlled conditions. However enzymatic sensors are not
stable, and therefore require regular replacement.
Non-enzymatic glucose sensors (NEGS) are the focus of intense
research because they offer the major benefits of increased stability
and lower maintenance,49 the potential for continuous glucose
monitoring without sensor replacement, and the possibility to
detect glucose non-invasively.
NEGS can be roughly divided into two categories: sensors
that combine artificial enzymes for the electrochemical detec-
tion of oxidized glucose, and sensors that physically detect the
glucose molecule. Artificial enzymes combined with electro-
chemical detection is analogous to the enzymatic approach
described in the last section, but specialized electrode surfaces
are used instead of enzymes.7,37,49,68 Some examples of these are
given in the next subchapter. For a fuller review on this topic,
readers are referred to reviews by Toghill and Compton (2010),
Park et al. (2006), Wang (2015), and Zaidi and Shin (2016).3,7,49,68
Physical glucose detection, on the other hand, is based on
detecting specific properties of the glucose molecule. This
is commonly done with optical spectroscopy, dielectric and
impedance spectroscopy, and electric measurements.44,52,69,70
The optical approaches include vibrational spectroscopy,
i.e. infrared (IR)22,71,72 and Raman spectroscopy,41,53,73–76 and
fluorescence spectroscopy.13,77
One of the benefits of non-enzymatic glucose detection may
lie in the potential to detect different glucose anomers, as well
as differentiate between them. Vibrational spectroscopy can be
used to clearly identify and distinguish glucose anomers, due to
small differences in the spectra. The a-D-glucose and b-D-glucose
anomers can be clearly distinguished in IR-spectra78 and Raman
spectra.29,79,80
In the case of approaches using artificial enzymes, it is more
difficult to determine the impact of the anomeric effect. Not
much research has been done in this direction, but there seems
to be a preference for selective electrodes to oxidize a-D-
glucose.7 More detailed electrochemical analysis of glucose
anomers is required, and electrode materials and surfaces
should be assessed on the anomer selectivity for higher detec-
tion accuracy.
Stabilization of a glucose anomer on a functionalized sub-
strate improves the accuracy of glucose detection immensely
for all techniques. Dingari et al. (2012) used albumin on gold
electrodes to stabilize the glucose anomers75 for Raman detec-
tion. Similar results have been shown using bis-boronic acid
and other molecules derived from boronic acid.3,6,49,81 The
glucose molecule does not interconvert between anomers once
it is bound. The boronic acid derivatives have been shown to
work for glucose detection in fluorescence, impedance, and
Raman measurements.3
This approach has yielded promising results for more
accurate glucose detection. However, a current limitation is
that boronic acid is even more selective for fructose than for
glucose.49 Further, the glucose binds to the electrode resulting
in a saturation of the electrode surface over time, rendering it
unresponsive. The reaction is, however, principally reversible,
and the reaction is pH dependent. Phenyl-boronic acid deriva-
tives can be tailored for the necessary binding strength and
specificity, opening up many possibilities for further research
towards continuous glucose monitoring with these stabilizing
agents combined with new glucose detection technologies.15
Artificial enzymes
Early research used pure metal electrodes, usually Pt, to oxidize
glucose. The glucose concentration is amperometrically deter-
mined by oxidizing the glucose molecule, and measuring the
resulting current. However, glucose is chemically very stable,
resulting in poor detection accuracy. More recent research has
demonstrated that by varying electrode composition and (nano)
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be enhanced, thereby improving charge transfer efficiency.3,7,49,68 In
electrochemical measurements, increasing the surface area of the
electrode increases the number of glucose molecules for detection,
and therefore the detection signal. The most straightforward
method to achieve this is to use roughened or nanostructured
electrodes. A considerable range of materials has been investigated
in this context, and the results are discussed in a comprehensive
review by Toghill and Compton in 2010,7 and in a more recent
review of nanostructured electrodes by Zaidi and Shin in 2016.68 In
addition, there is a review on metal nanostructures as artificial
enzymes by Tee et al. (2016) which focusses on the linear detection
range and the LOD.82 We will briefly highlight some commonly used
electrode materials and structures.
Copper oxide (CuO) is easily fabricated, low cost and has
shown good potential as an electrode material for glucose
detection. As a result CuO films and nanostructures have been
widely investigated. Annealing CuO at high temperatures in
order to remove all the water from the material, results in a
highly porous, stable, nanostructured film.83 It was shown that
these structures can detect glucose concentrations between
0.40 mM to 2.00 mM. CuO nanoparticles deposited onto other
substrate materials have been tested and also demonstrate high
selectivity for glucose.68 Other structures include CuO nano-
wires on Cu and CuO nanoflowers.84,85
Gold (Au) is stable, biocompatible and conductive, making it
a popular electrode material. Gold nanostructures are easily
synthesised, and in the last decade Au nanoparticles were
shown to be very effective for glucose oxidation.7
Electrodes of combined metals have been shown to have
improved electrocatalytic activity in comparison to single metal
electrodes due to functionalization of the surface.68 Au nano-
particles deposited on NiO proved to work well, in addition, positive
results came from Pt–Pd on Au (LOD of 20.6 mM)86 or graphene.87
Co8S9 has been used as an artificial enzyme.
88 It has been
reported to detect both glucose and hydrogen peroxide with an
LOD of 0.45 mM, and a linear response between 21.50 mM and
1.18 mM.
Co3O4 doped with Sn has had promising results.
89 Sn improves
the conductivity of Co3O4 significantly. The linear response was
reported between 2 mM and 0.5 mM; and 0.6–5.5 mM, with an
LOD of 100 nM.
Nickel hydroxide/3D graphene electrodes with an LOD of
24 nM90 were reported in combination with electrochemical
measurements.
Frequency-resolved spectroscopy
Direct current (DC) measurements can be applied to detect
glucose concentrations via electron transfer between the
glucose molecule and the electrode (glucose oxidation) as dis-
cussed above. Alternatively, variations in glucose concentration
will impact the conductivity of the bodily fluid. However DC
conductivity measurements on body fluids, particularly sweat,
will further be strongly influenced by temperature, pH as well as
other biomarkers and salts. For more accurate glucose detection,
frequency-resolved techniques, such as impedance, admittance,
dielectric and terahertz (THz) spectroscopies, offer more insight.
These techniques monitor the response of the sample to a modu-
lated electric field. The electric field is modulated over a range of set
frequencies during the measurement, resulting in a frequency
spectrum with information about relaxation processes. The differ-
ence between the techniques is the frequency range under inves-
tigation. Fig. 6 illustrates the frequencies in the electromagnetic
spectrum.91 Impedance and admittance spectroscopy are electrical
measurements and are used to study frequency windows between
sub Hertz (Hz) and 106 Hz. The results yield information about
the resistive/conductive and capacitive response of the sample.
Dielectric spectroscopy is a non-contact method used to study the
frequency response of a sample at around 107–109 Hz, and typically
yields information about structural properties and intermolecular
interactions. THz spectroscopy is an optical spectroscopy that
probes the frequency response of a sample in the THz regime,
i.e. at 1012 Hz. This enables the investigation of even faster
relaxation processes and interactions than with impedance or
dielectric spectroscopy.
The glucose molecule exhibits several relaxation processes at
characteristic frequencies, which can be related to distinct
physical processes. At low frequencies (sub Hz – 103 Hz) the
translational motion of the glucose molecule in solution,
i.e. DC conductivity, dominates the frequency spectrum. At
higher frequencies (103–107 Hz) a relaxation related to coopera-
tive interactions between the glucose molecules is observed.
Further relaxation processes at intermediate frequencies have
been observed for cooled samples with higher glucose
concentrations.92 Their origin is under debate, but they have been
linked to clustering of glucose molecules.93 These processes are
most likely irrelevant for glucose detection under physiological
conditions. THz spectroscopy has been used to probe charac-
teristic glucose–water interactions.94
Skin impedance was measured by Caduff et al. (2009) in a
non-invasive glucose monitor using impedance.52 Measure-
ment sensitivity can be increased by using electrodes with
nanostructures90 or by binding glucose to the electrode surface.
The accuracy of impedance measurements for glucose detec-
tion were significantly enhanced with a pyrene-based boronic
acid,95 however the functionalized group bonds with glucose,
making this specific derivative unsuitable for continuous
glucose monitoring.15
Fig. 6 The electromagnetic spectrum. The specific frequencies ranges
that are relevant for different optical spectroscopic techniques are
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Kim et al. (2015) made a reusable biosensor chip for mea-
suring at radio frequencies.96 The impedance, capacitance and
other properties could be derived. These results (especially the
impedance) showed linear responses to glucose concentrations.
The measurements take 2 seconds and the chip can easily be
flushed and reused. It showed a LOD of 0.033 mM.
The company gluco-wise published their in vivo results in
Nature.97 Their approach can measure dielectric permittivity
through a finger or earlobe at radio wave frequencies. The
set-up can successfully detect a glucose spike in humans, but
the signal remains too uncertain for determining the exact
concentration. The LOD was reported to be 0.4 mM.
Photo-acoustic spectroscopy is based on the principles
that higher glucose concentrations result in higher acoustic
pressure. A device sends ultrasonic waves through the tissue at
high frequencies (20 kHz).3,68,98 Acoustic spectroscopy works by
radiating certain wavelengths (usually radiowaves) through a
sample (or skin) and measuring the response.
Lee et al. (2015) demonstrated a sensor based on THz nano-
antennae that could detect many analytes including glucose.99
The sensor could detect differences in D-glucose concentrations
varying over 3 orders of magnitude, from 10 to 44000 mg dL1.
Optical spectroscopy
The interaction of light with a molecule is very specific to its
chemical structure, and can therefore be exploited for detec-
tion. Light incident on a sample may be absorbed, transmitted,
reflected or scattered. For chemical identification, the detection
of absorbed or scattered light is most relevant. The energy of
the absorbed photon may promote an electron to a higher
energy state, resulting in the subsequent emission of light, or
the dissipation of heat. The benefit of using optical spectro-
scopy is that pH and temperature fluctuations are not critical
for the measurement. Further, there is good flexibility in
performing measurements, and optical signals are generally
harmless to the skin.
There are, however, hurdles for applying optical spectroscopy
in real applications for glucose detection. These are related to
inhomogeneous samples, poor signal-to-noise due to low glucose
concentrations, and the presence of other molecules with similar
optical properties. Further, invasive calibration of the measure-
ment is often necessary.50 Considerable research into optical
spectroscopy of different bodily fluids for glucose detection has
been done, as well as optical measurements of the skin.12 The
following techniques can mostly also be used in combination with
enzymatic substrates for a higher sensitivity.
Fluorescence spectroscopy
Fluorescence spectroscopy is used to monitor the emission of
visible light from optically excited molecules. Fluorescent
molecules are called fluorophores. Absorption of a photon
promotes the fluorophore into the excited state, after which it
returns to the ground state via emission of a photon with a
characteristic energy. Glucose does not fluoresce, and must
therefore be combined with a fluorophore for detection. The
best fluorophores are conjugated molecules such as dyes,
conducting polymers and carbon nanotubes. The fluorophore’s
emitted wavelength changes due to the interaction with
glucose. Via the change in signal, the concentration of glucose
can be detected.77 Many variations of this approach have been
tested, including stabilizing glucose anomers with boronic acid
on a fluorophore.3,6,14
Vibrational spectroscopy
The most widely used vibrational spectroscopic method is Infra-
Red (IR) spectroscopy.22 Infrared spectroscopy (IR) is a chemical
analysis method that investigates the absorption of infrared
radiation in the wavelength range between 700 and 2500 nm
by molecular vibrations. The wavelength absorbed by the mole-
cule corresponds to energies of specific vibrations and rotations
of bonds within the molecule. The challenges for glucose detec-
tion with IR are that the scattering is very high, glucose con-
centrations are too low for accurate detection, water yields a
large peak that masks the glucose signal, and heterogeneous
distributions of glucose can falsify the measurement.100 Raman
spectroscopy is an analogous technique to IR, but the physical
background of Raman spectroscopy is often considered less
intuitive than the physical background of IR spectroscopy. While
IR probes the change in dipole moment associated by light
absorption by a vibrational mode, Raman probes the change
in polarizability associated with light interacting with a vibra-
tional mode. The methods are complementary, and if a mode is
Raman active it is not IR active and vice versa. A Raman
measurement is performed by exciting the sample with a laser
and detecting the Raman shifted (inelastic scattered) light. The
Raman signals are weaker than IR signals, but Raman spectro-
scopy presents several advantages. Firstly, water does not give as
prominent features in Raman spectra, IR is performed in
transmission and requires substrates that are transparent in
the IR wavelength range, while Raman spectroscopy measures
scattered light and can therefore be performed on any surface,
including opaque substrates. This enables the use of specialized
substrates that enhance the Raman signal, i.e. Surface Enhanced
Raman Spectroscopy (SERS).
Both vibrational spectroscopy methods can be applied to
accurately identify and distinguish molecular species via the
characteristic energy of molecular bonds. Further, the signals
are stoichiometric; the signal intensity is directly proportional
to the concentration of the analyte.
In 2006 Stuart et al. demonstrated in vivo Surface Enhanced
Raman Spectroscopy (SERS) using silver film over nanospheres
(AgFON).41 Electrode nanostructures like gold nanostars have a lot
of potential as electrodes for SERS, showing a LOD of 5 mM.76
Recently organic layers were demonstrated as interesting SERS
substrates. Yilmaz et al. (2017) synthesized a large thiophene-
based molecule (DFH-4T) which enhanced the Raman signal by
3.4 104, and coated it with a thin gold layer to enhance the signal
by 1010.101 Research is also focussed on electrode nanostructures
or glucose-binding structures like albumin as well as different
molecules based on boronic acid. Pandey et al. (2017) showed the
effectiveness of chemometric algorithms to determine the concen-
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The specificity of both Raman and infrared techniques is
remarkable, and the a-glucose and b-glucose anomers yield clear
differences in both spectra. The IR spectrum of the glucose
anomers is shown in Fig. 7, with the a-glucose spectrum on the
top and the b-glucose spectrum on the bottom. Specifically, the
relative intensities of the peaks at 1480, 1360 differ, and two extra
peaks for a-D-glucose appear between 750 cm1 and 900 cm1.
The peak at 1360 cm1 represents the C–H bending at the
anomeric centre. The peaks between 780, 840 and 915 cm1 are
all related to C–H deformation at the anomeric centre.102 These
three peaks at a similar energy can also be seen in the Raman
spectra. The peak at 900 cm1 is very clearly due to the b-D-glucose
anomer as shown in detail in Fig. 8. The anomeric ratio can best
be calculated from the peaks around 900 cm1.29
Autonomous insulin delivery system
An autonomous electrode-free glucose monitor was demon-
strated by using synthetic polymer gel in combination with a
phenyl-boronic acid derivative and insulin. The insulin-filled
gel was tested on mice. It can be used as a synthetic pancreas as
it releases insulin automatically when sugar levels rise. The gel
lasts for 3 weeks before needing to be replaced.15 They mention
a LOD of less than 100 pM. The mechanism of releasing insulin
is inventive. When there is a high concentration of glucose, the
glucose binds to the boron polymer in the gel. The binding of
glucose induces a hydration of the gel. This hydration induces
the release of insulin from the gel, and it can subsequently
diffuse into the bloodstream.
Improving accuracy in non-invasive
glucose detection with hybrid
approaches
Glucose detection based on a single technique is fundamentally
limited by the sensitivity and accuracy of the technique itself.
This is critical for quantifying low glucose concentrations in the
presence of other molecular species. To circumvent this, it is
possible to use a combination of complementary techniques for
glucose detection, as well as sensors for monitoring the properties
of the environment. To date, combining techniques for higher
accuracy is not common practice.103 Harman-Boehm et al. (2010)
combined ultrasonic, electromagnetic and thermal sensors and
averaged the results to obtain higher accuracy (96% of measure-
ments are within the clinically accepted range). Song et al. (2014)
combined IR and impedance for glucose monitoring.71 The group
used an Artificial Neural Network (ANN) for analysing the results.
They had an MARD of 8.3%. Simulations of combining techni-
ques was done by Asaduzzaman et al. (2016), they propose IR
spectroscopy in combination with ultrasonic measurements.98
The error was well within the required 20% range. Jintao et al.
combined Raman and NIR spectroscopy and had a Relative
Standard Deviation (RSD) of below 4%.72 Similarly, Amaral et al.
(2017) combined IR with impedance.70 Caduff et al., (2009)
combined photoelectric spectroscopy and dielectric measure-
ments to monitor glucose in skin and underlying tissue, with
an MARD of 27%.52 Generally combining multiple techniques
presents a cost issue, as well as increasing the size and complexity
of the sensor. However, it may be a promising strategy if the
accuracy and precision can be improved beyond those of conven-
tional glucose sensors.
The current market
Until 2010 the test strips and glucose meter was the only self-
testing method available to diabetics. Though the number of
test strip providers increased, four large companies dominate
90% of the test strip market (Abbott, Bayer, LifeScan, Roche),
making market entry difficult for newcomers. Innovations in
self-testing began to emerge in the late 00’s, and since then the
Fig. 7 Infrared spectra of D-glucose anomers. Top: a-D-Glucose
spectrum. Bottom: b-D-Glucose spectrum. Reprinted from ref. 80 with
permission from Elsevier.
Fig. 8 Raman spectra of a-D-glucose and b-D-glucose centered at
900 cm1 to show the anomeric region. Reprinted with permission from
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market shifted towards continuous CGM devices.104 Despite the
massive demand and urgency for new innovations in glucose
detection, in the last decades the enormous effort in research
has only led to a few commercially successful products. This may
be due to the fact that it is generally difficult for newcomers to
enter the fiercely competitive medical market, with its lobby
groups and administrative hurdles. In Europe, clinical trials are
required in each independent country, which is expensive and
time intensive. Further, the motivation to patent and develop
new technologies quickly may mean that many researchers are
not publishing their results and the developments in emerging
technologies are not publically documented. Several larger
companies have released continuous glucose meters (CGMs)
based on enzymatic sensors, including Abbot, DEXCOM, and
Medtronics.13,17,50 Senseonics introduced Eversense on the
market, a non-enzymatic chemical sensor.13,105 Until 2010
CGM devices were not accurate enough to contribute to useful
measuring and monitoring of patient glucose levels.106 However,
the most recent CGMs are more accurate and do improve patient
control.106 CGMs measure the glucose in blood or interstitial
fluid using the commonly applied GOx or GDH enzyme com-
bined with a calibrated glucose meter at very regular intervals
(between 1 and 5 minutes, depending on the system). They require
weekly or biweekly sensor replacements, with the exception of
Eversense from Senseonics. Eversense applies a fluorescent
glucose-selective polymer, and has an official lifetime of 90 days.
Kropff et al. (2017), however, has shown 40% of sensors to be
working after an impressive 180 days.105 Regular calibration
with blood samples is still recommended as these technologies
are still being optimized. The systems are not always covered
by insurance, and as a result, often expensive for patients.
Freestyle Libre however, is insured in many countries and it is
expected that other CGMs will follow worldwide. Several
reviews on commercial CGMs exist; among others Lin et al.
(2017) and Cappon et al. (2017).13,17
Non-enzymatic CGMs are not yet on the market for
patient use, but some are already being tested on patients.
Raman4Clinics, for example, is a platform for encouraging
Raman spectroscopy as a medical analytical device. There are
more non-invasive CGM systems emerging on the market.
Several products are currently being tested and are expected
on the market in 2018. Two of these products are K’Watch
(www.pkvitality.com) and Gluco Wise (www.gluco-wise.com).
The K’Watch works with biosensors and nanoneedles which
measure glucose in interstitial fluids. The biosensor needs
to be replaced every month. GlucoWise uses low-frequency
radio waves to measure the glucose in the blood. Neither of
these monitor continuously but they can measure the glucose
concentration at the press of a button. These companies do
not always give full disclosure of their technologies, because
they want to secure their intellectual property and/or market
position. Table 3 summarizes current and emerging technolo-
gies in CGM.
Summary and outlook
Research in the field of glucose detection is thriving, which is
positive for the vast and growing number of diabetic patients.
New results for enzymatic and non-enzymatic detection are
promising for the development of CGM devices. Commercial
CGMs are on the market, and the benefits of regular and




Medtronics Enzymatic detection in interstitial fluid One week lifetime 9.1–13.6%
Ihealth Gluco Smart Enzymatic detection in blood Invasive
DEXCOM G5 Enzymatic detection in interstitial fluid Expensive weekly replacement is
necessary; and a calibration
every 12 hours.
9%
DEXCOM G6 Unknown. . . but no calibration is necessary. The other
products from DEXCOM suggest that it is enzymatic.
Available in 2018
Abbott’s Freestyle Libre Enzymatic detection in interstitial fluid Expensive 2 weekly
replacement is necessary
11.4%
Eversense Senseonics Fluorescent polymer for interstitial fluid analysis 90 day lifetime 11.4%
Only approved in Europe
Body insertion needs to
be done by a doctor
K-watch Biosensing (enzymatic sensing) in interstitial
fluid (still in development)
Gluco-wise Radio-wave frequency detection in blood
(still in development)
Not accurate for specific
concentrations
NovioSense Enzymatic detection in tears
(still in development)
Considered non-invasive,
but needs to be implanted in the eye
Bigfoot Glucose meter + automatic insulin pump
(still in development)
Tandem Animas Insulet These companies will use DEXCOM’s G5 meter in




Enzymatic detection via a circuit inside a soft
contact lens. The data could be sent directly to a
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continuous monitoring has been recognized by patients, health
care experts, and insurance companies. Most of the commer-
cially available CGMs monitor glucose in interstitial fluid.
Interstitial glucose levels may indeed be more relevant for
preventing long term damage due to hyperglycaemia. However
this is still an invasive measurement. In addition current CGMs
are enzymatic systems and thus need regular sensor replace-
ments. Enzymatic glucose sensors have very high sensitivity
and selectivity, which is why most commercial sensors are in
fact enzymatic. Enzymatic sensors are, however, critical for
applications that rely on stability for long term usage.
Non-enzymatic systems for monitoring glucose, in contrast,
demonstrate better stability, but more research is needed to
overcome other issues such as interactions with other mole-
cules, anomeric selectivity and miniaturizing the detection
system. The choice of bodily fluid for non-invasive detection
isn’t a trivial one. The possible body fluids for non-invasive
glucose detection, including tears, sweat, and saliva, all have
lower glucose concentrations than blood, and measurement
accuracy and precision are therefore the major challenge.
Interstitial fluid seems the most practical for non-invasive
CGMs because it is the fluid surrounding the nerve cells, and
the location just below the skin, but there are problems to
overcome, such as fluid extraction and varying pH, which
affects the anomeric ratio of glucose. This means that fluctua-
tions in interstitial pH need to be accounted for. Tear fluid and
sweat also have many advantages, but present equally difficult
challenges.
Breakthroughs in non-invasive glucose detection require
interdisciplinary efforts to fully understand the challenges,
and required innovations to overcome current technical
limits in glucose detection for self-monitoring devices. Future
research will need to focus on both fundamental as well as
applied questions, such as electrode structures and geometries,
device miniaturization, glucose-binding surfaces and mole-
cules, as well as (theoretical) insight into the mechanism of
glucose mutarotation, including the effect of pH and tempera-
ture, the effect of environment on the electrical and optical
properties of glucose. Overcoming these challenges can enable
the development of smart wearable devices for non-invasive
CGM. This would improve the quality of life of hundreds of
millions of people by improving measures for the prevention
and treatment of diabetes.
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L. Dohnalová, M. Pevsner-Fischer, R. Bikovsky, Z. Halpern, E. Elinav and
E. Segal, Cell, 2015, 163, 1079–1095.
17 T. Lin, A. Gal, Y. Mayzel, K. Horman and K. Bahartan, Curr. Trends
Biomed. Eng. Biosci., 2017, 6, 1–8.
18 M. McCaul, T. Glennon and D. Diamond, Curr. Opin. Electrochem.,
2017, 3, 46–50.
19 J. Kim, A. S. Campbell and J. Wang, Talanta, 2018, 177, 163–170.
20 N. S. Oliver, C. Toumazou, A. E. G. Cass and D. G. Johnston,
Diabetic Med., 2009, 26, 197–210.
21 M. Lazarte, New ISO standards, https://www.iso.org/news/2013/06/
Ref1749.html.
22 J. Yadav, A. Rani, V. Singh and B. M. Murari, Biomed. Signal Process.
Control, 2015, 18, 214–227.
23 A. S. Higioka, R. C. M. Rudolf-Oliveira, F. Martinello and
M. L. Bazzo, Accredit. Qual. Assur., 2016, 21, 143–149.
24 L. Ekhlaspour, D. Mondesir, N. Lautsch, C. Balliro, M. Hillard,
K. Magyar, L. G. Radocchia, A. Esmaeili, M. Sinha and S. J. Russell,
J. Diabetes Sci. Technol., 2017, 11, 558–566.
25 W. Brown, Organic Chemistry, 1995, pp. 718–740.
26 S. Ege, Organic Chemistry, 1989.
27 E. Anslyn and D. Dougherty, Modern Physical Organic Chemistry,
University Science Books, 2006.
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